Maternal Embryo Interaction in Recurrent Miscarriages

Overview

Background of the study: The etiology of recurrent miscarriage (RM, defined as three or more consecutive miscarriages without any proven maternal or fetal cause), remains undiagnosed in more than 50% of cases. In these cases it is generally considered that a disturbance in the normal mother-embryo interactions is a causal factor. This disturbance may be based on a dysregulation of embryo invasiveness and/or decidual acceptance (e.g. altered decidualization; endometrial changes in preparation for the acceptance of a putative pregnancy). Moreover, dysfunctional maternal immune regulatory natural killer (NK) cells, implicated in tolerance induction and trophoblast invasion,may also underlie the occurrence of RM. The Selection Failure hypothesis for RM suggests that super-receptive endometrium (possibly due to increased embryo invasiveness and/or decidual acceptance and/or dysregulated immune cell function) may allow 'poor quality' embryos to implant and present as a clinical pregnancy before miscarrying. Fundamental knowledge on mechanisms of embryo implantation, decidual function and maternal immune reactivity in successful pregnancies has accumulated over the past 5 years. This study aims to investigate whether dysregulation of (one of) these mechanisms may underlie RM. Objective of the study: To test The Selection Failure hypothesis by assessing A) the degree of embryo invasiveness and decidual acceptance (the quality of decidualization, endometrium-embryo communication and endometrial stromal cell (ESC) migration) and B) the angiogenic capacity of decidual NK (dNK) cells, in order to elucidate the pattern of the mother-embryo equilibrium in women with RM.

Full Title of Study: “The Maternal-embryo Interaction and Its Role in the Etiology of Recurrent Miscarriages”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2011

Arms, Groups and Cohorts

  • Recurrent miscarriage group
    • Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
  • Control group
    • Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).

Clinical Trial Outcome Measures

Primary Measures

  • Embryo survival on decidualized ESCs of RM patients or fertile controls (Embryo survival as an indirect measure of embryo invasiveness)
    • Time Frame: 2 years
    • Embryo survival as an indirect measure of embryo invasiveness

Participating in This Clinical Trial

Inclusion Criteria

1. Women with unexplained recurrent miscarriages (three or more first trimester miscarriages). 2. Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage). 3. Age 18 – 40 years. 4. Willing and able to give informed consent. Exclusion Criteria:

1. Any identifiable causes of recurrent miscarriages; antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG or IgM]), other recognised thrombophilic conditions (testing according to usual clinic practice), intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram or hysteroscopy), submucous fibroids and tests initiated only if clinically indicated such as tests for diabetes, thyroid disease and SLE 2. Undergoing treatment (hormonal) 3. Women using oral contraception or having an intra uterine device.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • UMC Utrecht
  • Provider of Information About this Clinical Study
    • Principal Investigator: Bart CJM Fauser, Professor – UMC Utrecht
  • Overall Official(s)
    • Cobi J Heijnen, Prof. dr., Principal Investigator, UMC Utrecht

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.